April 16, 2014

Among severely obese people, vitamin D may make the difference between an active and a more sedentary lifestyle, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism on Tuesday.

April 15, 2014

Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

March 26, 2014

Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.

March 26, 2014

Perrigo announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products.

March 21, 2014

Actavis earlier this week announced that it has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (methylphenidate transdermal system).

March 20, 2014

Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

March 17, 2014

A recent audience-research study conducted by Nielsen found that among Cardinal Health's digital advertising network for retail pharmacies, called Pharmacy Health Network, half of viewers surveyed (49%) indicated that they felt encouraged to discuss a product or brand they had seen on Pharmacy Health Network with their pharmacist, and 48% indicated that after seeing ads on Pharmacy Health Network, they felt motivated to discuss those products or brands with their physicians.

March 13, 2014

The Cardinal Health Foundation and the Ohio State University College of Pharmacy have announced the introduction of the Medication Safety toolkit, the fifth in a series of interactive toolkits designed to help reduce the abuse of prescription drugs.

March 13, 2014

Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

March 3, 2014

Cardinal Health Specialty Solutions on Monday announced the acquisition of privately held Sonexus Health, a Dallas-based company that offers a range of patient access and specialty commercialization services.

February 28, 2014

Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash.

February 18, 2014

Actavis and Forest Labs. announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

January 31, 2014

Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.

January 30, 2014

The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning.

January 28, 2014

Actavis announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co. to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., an Actavis subsidiary based in Foshan, China.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

January 22, 2014

HealthSpot has formed a strategic partnership with MedAvail Technologies, which created the MedAvail MedCenter telepharmacy kiosk, to enable HealthSpot station locations to provide pharmacy services in addition to acute care telehealth services in locations where there is no retail pharmacy, such as employer sites and community locations.

January 21, 2014

Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe.

January 21, 2014

Actavis confirmed that the U.S. District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).

January 15, 2014

In its newest educational program, the Generation Rx Initiative mixes online learning with video games released Wednesday to promote learning about the dangers of prescription drug misuse and abuse.

January 15, 2014

Perrigo on Tuesday announced that it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to prescription-only Vanos Cream 0.1%.